20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

José Trigo; B.C. Cho; K. Park; N. Girard; Santiago Viteri; Pilar Garrido; Matthew Krebs; M. Thayu; R.E. Knoblauch; J. Xie; J.M. Bauml; R.W. Schnepp; A. Londhe; P. Mahadevia; N. Leighl

doi:10.1016/j.annonc.2022.02.029

20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

José Trigo, B.C. Cho, K. Park, N. Girard, Santiago Viteri, Pilar Garrido, Matthew Krebs, M. Thayu, R.E. Knoblauch, J. Xie, J.M. Bauml, R.W. Schnepp, A. Londhe, P. Mahadevia, N. Leighl

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S38-S39
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.02.029
Publication status	Published - 1 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.02.029

Cite this

Trigo, J., Cho, B. C., Park, K., Girard, N., Viteri, S., Garrido, P., Krebs, M., Thayu, M., Knoblauch, R. E., Xie, J., Bauml, J. M., Schnepp, R. W., Londhe, A., Mahadevia, P., & Leighl, N. (2022). 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Annals of Oncology, 33, S38-S39. https://doi.org/10.1016/j.annonc.2022.02.029

@article{5535b7c24a1e412497b48c0cd43b5cdd,

title = "20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)",

author = "Jos{\'e} Trigo and B.C. Cho and K. Park and N. Girard and Santiago Viteri and Pilar Garrido and Matthew Krebs and M. Thayu and R.E. Knoblauch and J. Xie and J.M. Bauml and R.W. Schnepp and A. Londhe and P. Mahadevia and N. Leighl",

year = "2022",

month = apr,

day = "1",

doi = "10.1016/j.annonc.2022.02.029",

language = "English",

volume = "33",

pages = "S38--S39",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Trigo, J, Cho, BC, Park, K, Girard, N, Viteri, S, Garrido, P, Krebs, M, Thayu, M, Knoblauch, RE, Xie, J, Bauml, JM, Schnepp, RW, Londhe, A, Mahadevia, P & Leighl, N 2022, '20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)', Annals of Oncology, vol. 33, pp. S38-S39. https://doi.org/10.1016/j.annonc.2022.02.029

TY - JOUR

T1 - 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)

AU - Trigo, José

AU - Cho, B.C.

AU - Park, K.

AU - Girard, N.

AU - Viteri, Santiago

AU - Garrido, Pilar

AU - Krebs, Matthew

AU - Thayu, M.

AU - Knoblauch, R.E.

AU - Xie, J.

AU - Bauml, J.M.

AU - Schnepp, R.W.

AU - Londhe, A.

AU - Mahadevia, P.

AU - Leighl, N.

PY - 2022/4/1

Y1 - 2022/4/1

U2 - 10.1016/j.annonc.2022.02.029

DO - 10.1016/j.annonc.2022.02.029

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S38-S39

JO - Annals of Oncology

JF - Annals of Oncology

ER -